A Pharmacist’s Perspective on Optimizing Therapy Selection and Deprescribing in Oncology: Jason Bergsbaken, PharmD, MBA, BCOP
Jason Bergsbaken, PharmD, MBA, BCOP, explains the value of pharmacist involvement in precision molecular tumor boards and end-of-life care discussions, highlighting their role in ensuring evidence-based therapy selection, patient-specific recommendations, and shared decision-making that aligns treatment with individual goals.
Navigating Biosimilar Mandates and Prior Authorization in a Value-Based Cancer Care Model: Jason Bergsbaken, PharmD, MBA, BCOP
Jason Bergsbaken, PharmD, MBA, BCOP, highlights the operational challenges of value-based oncology care while emphasizing the need to balance standardized treatment pathways with flexibility for personalized, biomarker-driven care.
Academic–Community Partnerships and Real-World Data in Value-Based Oncology: Jason Bergsbaken, PharmD, MBA, BCOP
Jason Bergsbaken, PharmD, MBA, BCOP, highlights the growing role of real-world data in validating or de-implementing therapies, the need for vigilant postapproval outcomes monitoring, and the value of academic–community oncology partnerships.
